The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial

被引:8
|
作者
Heimburger, Sebastian M. N. [1 ,2 ,3 ]
Hoe, Bjorn [1 ,4 ]
Nielsen, Chris N. [1 ]
Bergmann, Natasha C. [1 ]
Hartmann, Bolette [3 ,5 ]
Holst, Jens J. [3 ,5 ]
Vilsboll, Tina [1 ,2 ,4 ]
Dejgaard, Thomas F. [1 ,2 ]
Christensen, Mikkel B. [1 ,4 ,6 ,7 ]
Knop, Filip K. [1 ,2 ,3 ,4 ]
机构
[1] Univ Copenhagen, Gentofte Hosp, Ctr Clin Metab Res, Hellerup, Denmark
[2] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[3] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark
[4] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
[5] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark
[6] Univ Copenhagen, Bispebjerg Hosp, Dept Clin Pharmacol, Copenhagen, Denmark
[7] Univ Copenhagen, Bispebjerg Hosp, Copenhagen Ctr Translat Res, Copenhagen, Denmark
关键词
Adipose tissue; Continuous glucose monitoring; GIP; Glucose-dependent insulinotropic polypeptide; Glycaemic control; Glycaemic time in range; Hypoglycaemia; Hypoglycaemic events; Insulin resistance; Insulin sensitivity; RECEPTOR AGONIST; GLUCAGON; HYPOGLYCEMIA; RESPONSES;
D O I
10.1007/s00125-021-05547-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis Type 1 diabetes is characterised by reduced glucagon response to hypoglycaemia, increasing the risk of insulin treatment-associated hypoglycaemia known to hamper glycaemic control. We previously reported a glucagonotropic effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) during insulin-induced hypoglycaemia in individuals with type 1 diabetes. Here we investigate the effect of a 6-day s.c. GIP infusion on time in glycaemic range as assessed by continuous glucose monitoring (CGM) in individuals with type 1 diabetes. Methods In a randomised, placebo-controlled, double-blind crossover study, time in glycaemic range (assessed by double-blinded CGM) was evaluated in 20 men with type 1 diabetes (18-75 years, stable insulin treatment >= 3 months, diabetes duration 2-15 years, fasting plasma C-peptide below 200 pmol/l, BMI 20-27 kg/m(2), HbA(1c) <69 mmol/mol [8.5%]) during two x 6 days of continuous s.c. GIP (6 pmol kg(-1) min(-1)) and placebo (saline [154 mmol/l NaCl]) infusion, respectively, with an interposed 7-day washout period. The primary outcome was glycaemic time below range, time in range and time above range. Results There were no significant differences in time below range (<3.9 mmol/l, p = 0.53) or above range (>10 mmol/l, p = 0.32) during night-time or daytime, in mean glucose, or in hypoglycaemic events as assessed by CGM. GIP altered neither self-reported hypoglycaemia nor safety measures. Compared with placebo, GIP significantly increased time in tight range (3.9-7.8 mmol/l) during daytime (06:00-23:59 hours) by [mean +/- SEM] 11.2 +/- 5.1% [95% CI 0.41, 21.9] (p = 0.02). Conclusions/interpretation Six-day s.c. GIP infusion in men with type 1 diabetes did not procure convincing effect on overall time in range, but increased time in tight glycaemic range during daytime by similar to 2 h per day.
引用
收藏
页码:2425 / 2431
页数:7
相关论文
共 50 条
  • [1] The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial
    Sebastian M. N. Heimbürger
    Bjørn Hoe
    Chris N. Nielsen
    Natasha C. Bergmann
    Bolette Hartmann
    Jens J. Holst
    Tina Vilsbøll
    Thomas F. Dejgaard
    Mikkel B. Christensen
    Filip K. Knop
    Diabetologia, 2021, 64 : 2425 - 2431
  • [2] Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial
    Heimburger, Sebastian M. N.
    Nielsen, Chris N.
    Calanna, Salvatore
    Holst, Jens J.
    Vilsboll, Tina
    Knop, Filip K.
    Christensen, Mikkel B.
    DIABETES OBESITY & METABOLISM, 2022, 24 (01) : 142 - 147
  • [3] Effect of liquid ubiquinol supplementation on glucose, lipids and antioxidant capacity in type 2 diabetes patients: a double-blind, randomised, placebo-controlled trial
    Yen, Chi-Hua
    Chu, Ying-Ju
    Lee, Bor-Jen
    Lin, Yi-Chin
    Lin, Ping-Ting
    BRITISH JOURNAL OF NUTRITION, 2018, 120 (01) : 57 - 63
  • [4] Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
    Dejgaard, Thomas Fremming
    Frandsen, Christian Seerup
    Hansen, Tanja Stenbaek
    Almdal, Thomas
    Urhammer, Soren
    Pedersen-Bjergaard, Ulrik
    Jensen, Tonny
    Jensen, Andreas Kryger
    Holst, Jens Juul
    Tarnow, Lise
    Knop, Filip Krag
    Madsbad, Sten
    Andersen, Henrik Ullits
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (03) : 221 - 232
  • [5] Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
    Kapitza, Christoph
    Dahl, Kirsten
    Jacobsen, Jacob B.
    Axelsen, Mads B.
    Flint, Anne
    DIABETOLOGIA, 2017, 60 (08) : 1390 - 1399
  • [6] Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
    Christoph Kapitza
    Kirsten Dahl
    Jacob B. Jacobsen
    Mads B. Axelsen
    Anne Flint
    Diabetologia, 2017, 60 : 1390 - 1399
  • [7] Effect of Lingliptin and Voglibose on metabolic Profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial
    Parthan, Girish
    Bhansali, Shobhit
    Kurpad, Anura, V
    Walia, Rama
    Bhat, Kishor
    Bhansali, Anil
    BMC PHARMACOLOGY & TOXICOLOGY, 2018, 19
  • [8] Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial
    Wegeberg, Anne-Marie Langmach
    Hansen, Christian Stevns
    Farmer, Adam D.
    Karmisholt, Jesper Scott
    Drewes, Asbjorn M.
    Jakobsen, Poul Erik
    Brock, Birgitte
    Brock, Christina
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (06) : 695 - 704
  • [9] Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial
    Hartemann, Agnes
    Bensimon, Gilbert
    Payan, Christine A.
    Jacqueminet, Sophie
    Bourron, Olivier
    Nicolas, Nathalie
    Fonfrede, Michele
    Rosenzwajg, Michelle
    Bernard, Claude
    Klatzmann, David
    LANCET DIABETES & ENDOCRINOLOGY, 2013, 1 (04) : 295 - 305
  • [10] Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study
    Schopman, J. E.
    Hoekstra, J. B. L.
    Frier, B. M.
    Ackermans, M. T.
    de Sonnaville, J. J. J.
    Stades, A. M.
    Zwertbroek, R.
    Hartmann, B.
    Holst, J. J.
    Knop, F. K.
    Holleman, F.
    DIABETES OBESITY & METABOLISM, 2015, 17 (06) : 546 - 553